Analyst Alerts: Medicines, Lululemon, Auxilium, Sirona Dental June 5th
Medicines Co. (NASDAQ:MDCO): Leerink says current bills in the House and Senate extend the market exclusivity period for new antimicrobial drugs by five years, and grant six additional months of data exclusivity for antibiotics with companion diagnostics. Leerink believes The Medicines Co.’s Oritavancin may qualify for five years of additional “antibiotic exclusivity,” which it feels could double the drug’s value to $4 per The Medicines Co. share. Leerink keeps an Outperform rating on shares of The Medicines Co.
Lululemon Athletica Inc. (NASDAQ:LULU): UBS expects Lululemon to report Q1 EPS of 30c, above guidance of 28c-29c, driven by comps and direct sales given higher inventories, product innovation, strong fashion, and product flows. The firm’s checks indicate Q1 markdowns were controlled and online selling was strong. The analyst expects Q2 sales upside but less than Q1 given softness in Canada and gross margin pressure. Shares are Buy rated with a $91 price target.
Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL): BofA/Merrill raised Auxilium’s price target based on positive Ph III results of Xiaflex in Peyronie’s disease. Shares are Buy rated.
Sirona Dental Systems Inc. (NASDAQ:SIRO): After meeting with Sirona’s management, Cantor Fitzgerald believes that the stock has more than baked in the headwinds facing the company. The firm reiterates a Buy rating on the stock.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.